Cambridge, Massachusetts-based drug developer Boston Pharmaceuticals today announced two separate licensing deals with leading pharma companies.
First up, Boston has in-licensed a portfolio of five early development programs from UK major GlaxoSmithKline (LSE: GSK). The portfolio includes two Phase II ready development candidates, one Phase 1-ready development candidate and two undisclosed preclinical programs with identified lead cPublishandidates. Financial terms of the transaction were not disclosed.
Boston will assume full responsibility from GSK to progress the clinical stage programs for:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze